Bruce K. Kowiatek

Blue Ridge Community and Technical College, USA

Title: Methylating Agents as Adjunct Therapy to Chemotherapeutic Alkylating Medications for Improved Outcomes in Chronic Lymphocytic Leukemia: A Case Study

---

Biography

Dr. Bruce K. Kowiatek earned his Bachelor’s in English Writing from the University of Pittsburgh in 1998, and his Doctorate in Pharmacy and Master’s in Business Administration from Shenandoah University in 2002. In addition to researching and investigating the origins of life for over 20 years, he has also published books and papers on a variety of topics, worked as a clinical pharmacist, and is currently full-time Allied Health Sciences Faculty at Blue Ridge Community and Technical College in Martinsburg, WV, USA.

Abstract

Although the non-enzymatic methylation of cytidine (C) by S-adenosylmethionine (SAM) and methylcobalamin  to 5-methylcytidine and its subsequent spontaneous deamination to thymidine (T) in DNA at physiologic pH and temperature has been known since the early 1980s and has been implicated in some C to T point mutagenic cancers, cancers in general, and chronic lymphocytic leukemia (CLL) in particular, display a global and promoter hypomethylation respectively of their DNA; SAM, therefore, sold as the over-the-counter (OTC) supplement SAM-e, as well as the OTC  methylcobalamin precursor cyanocobalamin may still possibly play a role as potential adjunct therapies in certain cancers, particularly those treated with alkylating chemotherapeutic agents used in CLL, much in the same way that folic acid is used as a rescue adjunct therapy when using antifolate chemotherapeutic agents. Clinical trials in support of this proposal were set to begin just prior to the COVID-19 pandemic but have been indefinitely postponed; however, while an ongoing case study employing this methylation protocol is currently underway with extremely positive results thus far, the protocol itself has since been implemented nationwide in the U.S., again with extremely positive results.